What is BPH?
Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that becomes increasingly common with age, affecting a large proportion of men from their fifties onward. As the prostate enlarges, it can compress the urethra and affect bladder function, giving rise to a cluster of lower urinary tract symptoms (LUTS). These symptoms generally fall into two overlapping categories: voiding symptoms (caused by physical narrowing of the outlet), which may include a weak or interrupted stream, straining to urinate, hesitancy, and a sense of incomplete bladder emptying - and storage symptoms (related to bladder irritability and neuromuscular tone), which may include urinary frequency, urgency, and nocturia (waking at night to urinate). Most men experience some combination of both, though the balance varies considerably from patient to patient, which is part of why no single intervention suits everyone equally.
Nutraceutical support for BPH-related symptoms works through several distinct mechanisms: hormonal, anti-inflammatory, antioxidant, and mild muscle relaxation. Because these ingredients act differently, patients may benefit differently depending on their symptom presentation. And, trialling a nutraceutical option under practitioner guidance (as an adjunct to conventional management) is a reasonable thing to consider.
Beta-sitosterol
How it works: Beta-sitosterol partially inhibits 5-alpha-reductase, the enzyme that converts testosterone into DHT - the hormone most responsible for prostate growth. It works via the same pathway as finasteride, though considerably less potently. It may also have some anti-inflammatory activity in prostate tissue.
Clinically, this means that beta-sitosterol is more likely to help with weak stream, straining, and incomplete emptying than with urgency or frequency, since it targets hormone-driven prostate growth (the growth of which creates a physical blockage) rather than bladder muscle tone. Its effect on DHT is milder than finasteride's, so expect a smaller improvement, not an equivalent one.
Clinical evidence: A review pooling four placebo-controlled trials in 519 men found beta-sitosterol was well tolerated and improved urinary symptom scores and flow in men with mild to moderate BPH; symptom scores improved by almost 5 points more than placebo, with better flow and less residual urine. It did not reduce prostate size compared with placebo, and long-term safety data remain limited.
Saw palmetto
How it works: Saw palmetto's fatty acids and plant sterols act through several routes at once: mild DHT reduction (similar principle to beta-sitosterol), a modest relaxing effect on the bladder neck muscle (same direction as alpha-blockers, much milder), and some anti-inflammatory activity.
Clinically, this means that due to multiple mechanistic pathways, Saw Palmetto may provide benefit for a broader symptom range than beta-sitosterol: the DHT-reduction component may aid the same outlet-narrowing symptoms (weak stream, straining, incomplete emptying) as beta-sitosterol, while the muscle-relaxing component adds potential coverage of urgency, hesitancy, and bladder neck-related obstruction. In principle, this makes it a candidate for patients with a more mixed symptom picture rather than one dominated by a single pattern. Real-world results vary largely between products, tracking with extract concentration and standardisation.
Clinical evidence: A review of 27 studies found saw palmetto alone provided little or no benefit for BPH symptoms, and two NIH-funded trials showed no improvement over placebo. That said, newer, more concentrated extracts have outperformed older, less standardised versions in head-to-head trials, suggesting product quality and standardisation play a meaningful role. Not all saw palmetto products are equivalent.
Lycopene
How it works: Lycopene is a potent antioxidant that protects prostate cells from oxidative damage. It also appears to interfere with growth signals that drive cell proliferation, calm inflammation, and support normal cell-to-cell communication, a process that tends to break down in abnormal cell growth.
Clinically, this means that lycopene may provide slower, cellular-level effects rather than acting on bladder muscle tone or urine flow directly. Lycopene is better positioned for long-term risk reduction than for relieving day-to-day urinary symptoms; it shouldn't be expected to noticeably improve flow the way beta-sitosterol or an alpha-blocker might. It has value as a supportive treatment.
Clinical evidence: The stronger body of evidence relates to prostate cancer risk reduction rather than day-to-day BPH symptoms, and trials on urinary symptoms specifically show only modest benefit. Because of this, lycopene is best used as a supporting ingredient within a broader treatment plan.
Why targeting multiple pathways makes sense
Because beta-sitosterol, saw palmetto, and lycopene each act on different aspects of BPH pathology - hormonal, anti-inflammatory/muscle tone, and oxidative/cellular, respectively - there's a sound rationale for combination treatments. Further, adding nutraceuticals onto prescription treatment may provide additional symptom support. Nutraceuticals have a place in a well-rounded, individualised patient treatment plan.
Conclusion
BPH is not a uniform condition, and symptoms vary from one patient to the next. Beta-sitosterol, saw palmetto, and lycopene each offer a distinct, evidence-supported mechanism, and understanding which symptom pattern each is more likely to influence allows for a more considered, individualised approach rather than a one-size-fits-all recommendation.
Disclaimer: None of the ingredients discussed here have been shown to reduce prostate size, and their supporting evidence relates to general wellness use rather than treatment of a diagnosed medical condition. As with any supplement regimen, patients should be encouraged to discuss nutraceutical options with their treating practitioner or pharmacist, particularly where they are also using prescription therapy such as an alpha-blocker or 5-alpha-reductase inhibitor, or undergoing routine PSA monitoring. Used thoughtfully and under guidance, nutraceuticals can be a reasonable adjunct within a broader, personalised approach to prostate health.